These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12679126)

  • 41. Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
    Ieko M; Tarumi T; Nakabayashi T; Yoshida M; Naito S; Koike T
    Front Biosci; 2006 Jan; 11():232-48. PubMed ID: 16146728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D; Hull R; Fareed J
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
    Drouet L
    Bull Acad Natl Med; 2003; 187(1):85-96; discussion 96-7. PubMed ID: 14556456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    J South Orthop Assoc; 2002; 11(4):182-8. PubMed ID: 12597061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis.
    Kalicki RM; Aregger F; Alberio L; Lämmle B; Frey FJ; Uehlinger DE
    Thromb Haemost; 2007 Dec; 98(6):1200-7. PubMed ID: 18064314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.
    Comp PC
    Pharmacotherapy; 2003 Jun; 23(6):772-87. PubMed ID: 12820819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fondaparinux: pharmacology and clinical experience in cardiovascular medicine.
    Toschi V; Lettino M
    Mini Rev Med Chem; 2007 Apr; 7(4):383-7. PubMed ID: 17430224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery.
    Bergqvist D
    Vasc Health Risk Manag; 2006; 2(4):365-70. PubMed ID: 17323590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PK evaluation of fondaparinux sodium for the treatment of thrombosis.
    Delavenne X; Frappé P; Zufferey P; Mismetti P; Laporte S; Bertoletti L
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):269-77. PubMed ID: 24359588
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of an Extended Interval Fondaparinux Dosing Regimen for Venous Thromboembolism Prophylaxis in Critically Ill Patients with Severe Renal Dysfunction Using Antifactor Xa Levels.
    Wahby KA; Riley LK; Tennenberg SD
    Pharmacotherapy; 2017 Oct; 37(10):1241-1248. PubMed ID: 28833353
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.
    Nutescu EA
    Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S5-13. PubMed ID: 17519445
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fondaparinux: a synthetic selective factor-Xa inhibitor.
    Wong NN
    Heart Dis; 2003; 5(4):295-302. PubMed ID: 12877762
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs.
    O'Shaughnessy DF
    Int J Clin Pract; 2004 Mar; 58(3):277-84. PubMed ID: 15117096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.
    Kubitza D; Haas S
    Expert Opin Investig Drugs; 2006 Aug; 15(8):843-55. PubMed ID: 16859389
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and experimental experience with factor Xa inhibitors.
    Viles-Gonzalez JF; Gaztanaga J; Zafar UM; Fuster V; Badimon JJ
    Am J Cardiovasc Drugs; 2004; 4(6):379-84. PubMed ID: 15554723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New anticoagulants for treatment of venous thromboembolism.
    Weitz JI
    Circulation; 2004 Aug; 110(9 Suppl 1):I19-26. PubMed ID: 15339877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New anticoagulants.
    Bauer KA
    Hematology Am Soc Hematol Educ Program; 2006; ():450-6. PubMed ID: 17124098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological effects and clinical applications of ultra low molecular weight heparins.
    Liu Z; Ji S; Sheng J; Wang F
    Drug Discov Ther; 2014 Feb; 8(1):1-10. PubMed ID: 24647152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prevention and treatment of venous thromboses and thromboembolism: pentasaccharides as novel anticoagulants selectively blocking Xe factor, their position and potential (data of the XIX International Congress on Thromboses and Hemostasis)].
    Averkov OV
    Angiol Sosud Khir; 2004; 10(3):12-23. PubMed ID: 15622389
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.
    Turpie AG
    Am Heart J; 2001 Aug; 142(2 Suppl):S9-15. PubMed ID: 11479485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.